Table 3 Factors that possibly affected the ORR of patients in EPAG+tacrolimus group and EPAG monotherapy group.
EPAG+tacrolimus | EPAG monotherapy | |||||
|---|---|---|---|---|---|---|
Patient characteristics | OR patients (N = 51) | NR patients (N = 25) | P-value | OR patients (N = 19) | NR patients (N = 19) | P-value |
Male/n (%) | 17 (33.3%) | 10 (40.0%) | 0.568 | 12 (63.2%) | 7 (36.8%) | 0.105 |
Age at EPAG initiation/years, median (range) | 45 (15–74) | 46 (14–83) | 0.899 | 48 (18–79) | 40 (14–78) | 0.271 |
Patients ≥ 60 years old/n (%) | 10 (19.6%) | 6 (24.0%) | 0.659 | 7 (36.8%) | 6 (31.6%) | 1.000 |
Interval between diagnosis and EPAG initiation/months, median (range) | 24 (6–480) | 36 (6–360) | 0.798 | 96 (6–468) | 53 (6–204) | 0.390 |
Refractory/n (%) | 27 (52.9%) | 13 (52.0%) | 0.938 | 12 (63.2%) | 7 (36.8%) | 0.105 |
NSAA/n (%) | 42 (82.4%) | 23 (92.0%) | 0.321 | 18 (94.7%) | 13 (68.4%) | 0.090 |
Platelet count/×109/L, median (range) | 13 (1–40) | 12 (1–261) | 0.430 | 9 (1–26) | 17 (2–26) | 0.584 |
Absolute neutrophil count/×109/L, median (range) | 1.51 (0.18–7.45) | 1.20 (0.36–4.68) | 0.366 | 1.76 (0.61–4.45) | 1.02 (0.80–3.3) | 0.238 |
Haemoglobin / (g/L), median (range) | 82 (24–159) | 81 (44–137) | 0.866 | 77 (30–167) | 63 (36–126) | 0.242 |
Reticulocyte count/×109/L, median (range) | 61.5 (11.5–230.5) | 21.6 (6.6–56.6) | 0.039 | 51.9 (16.6–220.6) | 50.1 (16.6–54.1) | 0.535 |
ALT/(U/L), median (range) | 17 (6–118) | 13 (5–101) | 0.591 | 18 (11–32) | 17 (8–32) | 0.645 |
Cr/(μmol/mL), median (range) | 80 (38–118) | 83 (56–168) | 0.558 | 93 (40–178) | 79 (43–178) | 0.437 |
Ferritin/(ng/mL), median (range) | 466 (12–4324) | 523 (10–4420) | 0.282 | 762 (12–9135) | 1530 (270–2567) | 0.285 |
Cytogenetics mutation presence/n (%) | 2 (3.9%) | 2 (8.0%) | 0.594 | 2 (10.5%) | 1 (5.2%) | 1.000 |
PNH clone presence at EPAG initiation/n (%) | 9 (17.6%) | 5 (20.0%) | 1.000 | 3 (15.8%) | 4 (21.1%) | 1.000 |
